Results 71 to 80 of about 252,541 (298)

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology
Development of chimeric antigen receptor T‐cell therapy has revolutionized the treatment of B‐cell malignancies, although challenges such as antigen escape and tumor heterogeneity often decrease treatment success. Modular CARs targeting multiple antigens
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
doaj   +1 more source

Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields

Advanced Science, EarlyView.
Canonical Y‐shaped antibodies recognize viral glycan shields through adaptive Fab assembly states shaped by glycan organization and somatic hypermutation. Structural analyses ofbroadly neutralizing antibodies VRC35 and VRC36 across glycoproteins of HIV‐1, influenza, SARS‐CoV‐2, and Lassa viruses reveal distinct Fab assembly states, spanning monovalent,
Jiaxuan Cheng, Evan M. Cale, Amirabbas Maghsoudi, Matthew S. Sutton, Nancy S. Longo, Rebecca A. Gillespie, Lingshu Wang, Ivan Kosik, Sue Chong, Atsuhiro Yasuhara, Tatsiana Bylund, Arne Schön, Prabhanshu Tripathi, Yaroslav Tsybovsky, Haotian Lei, Nicholas C. Morano, Allison B. Lupatkin, Abraham J. Morton, Zabrina C. Lang, Jordan E. Becker, Isabella R. Frascilla, Myungjin Lee, Ning Li, Cuiping Liu, Ryan S. Roark, Chen‐Hsiang Shen, I‐Ting Teng, David J. Van Wazer, Danyi Wang, Lingyuan Wu, Goran Ahlsen, Mike Castro, Haijuan Du, Michael J. Ernandes, Tiansheng Li, Bob C. Lin, Mark K. Louder, Krisha McKee, Jonah S. Merriam, Sijy O'Dell, Li Ou, Sergei Pletnev, David Prikryl, Qi Qiu, Sarah Rubin, Mallika Sastry, Stephen D. Schmidt, Asif Shajahan, Andrea R. Shiakolas, Sanjay Srivatsan, Baoshan Zhang, Qiong Zhou, Mark Connors, Jason G. Gall, Yicheng Guo, Rick K. Huang, Yaoxing Huang, Richard A. Koup, Q. Paula Lei, John R. Mascola, Reda Rawi, Leonid Serebryannyy, Lawrence Shapiro, Zizhang Sheng, David D. Ho, Patrick C. Wilson, Jonathan W. Yewdell, Theodore C. Pierson, Masaru Kanekiyo, Nicole A. Doria‐Rose, Peter D. Kwong, Tongqing Zhou   +71 more
wiley   +1 more source

Association Between Serum Ferritin and CD19/CD34 Expression in Pediatric Acute Lymphoblastic Leukemia [PDF]

Journal of Bioscience and Applied Research
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, characterized by malignant proliferation and accumulation of lymphoblasts in the bone marrow.
Karrar Tikki, Haider Jaffat
doaj   +1 more source

Chimeric antigen receptor–modified T cells: CD19 and the road beyond [PDF]

Blood, 2018
Abstract The ability to harness a patient’s immune system to target malignant cells is now transforming the treatment of many cancers, including hematologic malignancies. The adoptive transfer of T cells selected for tumor reactivity or engineered with natural or synthetic receptors has emerged as an effective modality, even for patients
Alexander I. Salter, Margot J. Pont, Stanley R. Riddell   +2 more
openaire   +2 more sources

A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control

Advanced Science, EarlyView.
Engineered STAb‐TON cells act as programmable living factories that continuously secrete inactive antibody modules, which assemble extracellularly into a functional T cell engager only upon small‐molecule administration. This externally controlled platform enables reversible, on‐demand regulation of antitumor immunity, establishing a new paradigm for ...
Susana Luengo‐Arias, Carmen Domínguez‐Alonso, Ivana Zagorac, Antonio Tapia‐Galisteo, Eva García‐Veros, Laura Rubio‐Pérez, Marina Gómez‐Rosel, Patricia Fuentes, Patricia Hernández‐López, Óscar Aguilar‐Sopeña, Laura Almagro‐Puente, Sonia Martínez‐González, Lucía Cañizares‐Moscato, María Rivas‐Sánchez, Belén Blanco, Ángel Ramírez‐Fernández, Laura Díez‐Alonso, Carmen Blanco‐Aparicio, Javier Arroyo‐Ródenas, Jorge Martínez‐Torrecuadrada, María L. Toribio, Pedro Roda‐Navarro, Anaïs Jiménez‐Reinoso, Luis Álvarez‐Vallina   +23 more
wiley   +1 more source

CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch

Frontiers in Immunology
CD19 chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of relapsed/refractory B-cell malignancies, achieving high remission rates. Nonetheless, 20%-40% of patients eventually relapse, classified as either CD19+ or CD19− relapse.
Jiawen Huang, Xiaobing Huang, Duonan Yu
doaj   +1 more source

Targeting antigen to CD19 on B cells efficiently activates T cells [PDF]

International Immunology, 2005
CD19 is a B cell-surface molecule that participates as an important regulatory signaling complex for antigen bound at the surface by Ig. Triggering of CD19 through its linkage with CD21 amplifies signals transduced through the Src family kinases and modulates B cell differentiation in response to antigen.
Jun, Yan, Martin J, Wolff, Julia, Unternaehrer, Ira, Mellman, Mark J, Mamula   +4 more
openaire   +2 more sources

SynNotch Receptors for Visualizing Immunoreceptor Force Transmission and Downstream Signaling In Vivo

Advanced Science, EarlyView.
A mechanically activated SynNotch reporter platform enables detection of force transmission through receptors as they mediate immune cell interactions. Targeting CD40 on B cells and TCR on T cells records force‐induced reporter activation across 2D coculture, 3D organoid, and implanted in mice, which also reveal force‐amplification of immune receptor ...
Menglan Li, Jintian Lyu, Kaitao Li, Ameya Dravid, Deepali Balasubramani, Amir H. K. Ashkezari, Hyun‐Kyu Choi, Gabriel A. Kwong, Ankur Singh, Cheng Zhu   +9 more
wiley   +1 more source

Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes [PDF]

Iranian Journal of Basic Medical Sciences, 2018
Objective(s): CD19 is a transmembrane glycoprotein of immunoglobulin superfamily. In order to treat lymphoma, monoclonal antibodies (mAb) can target different antigens, including CD19, CD20 and CD22 on the surface of B-cells.
Seyed Reza Banihahsemi, Ahmad Zavaran Hosseini, Fatemeh Rahbarizadeh, Davoud Ahmadvand   +3 more
doaj   +1 more source

Autophagy Orchestrates Anti‐Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP‐2 Axis in Colorectal Cancer

Advanced Science, EarlyView.
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng, Chaoying Wei, Zhitong Niu, Jinxin Chen, Guojie Long, Yingzhen Weng, Qiufeng Liu, Yue Jiang, Panpan Wang, Ronghua Zhang, Qiang Yu, Xiaojian Wu, Wenyu Wang   +12 more
wiley   +1 more source